This is achieved, in part, by ensuring compliance with applicable regulatory requirements and industry standards. Our environmental management system assures compliance with applicable environmental laws and regulations. We are committed to the continual improvement of environmental performance, including compliance assurance, natural resource conservation and pollution prevention.

With robust raw material testing and a comprehensive change control policy, these medical-grade concentrates and pre-colored formulations can help minimize risk and avoid non-compliance. KEY CHARACTERISTICS • Globally harmonized formulations are manufactured at four ISO 13485 certified medical sites, providing global consistency and increased security of supply • Documented change control available • A range of standard colors eliminates color matching to expedite development time • The portfolio includes compliant colors for use in: - Needle hub applications: ISO 6009 - Ophthalmic container closures (American Academy of Ophthalmology) REGULATORY SUPPORT • A library of pre-tested raw materials including: - ISO 10993-1 and USP biological evaluation - European Pharmacopeia 3.1.3/3.1.5 (polyolefin) - USP (polyethylene) - ICH Q3D elemental impurities • Registered Drug Master File (Type III) and/or Device Master File • Food contact established with FDA/EU* HEALTHCARE APPLICATIONS • Medical devices such as catheters, surgical and dental instruments, and drug delivery devices • Pharmaceutical packaging including vials and bottles • Diagnostics for blood analysis or In Vitro Diagnostics (IVD) PRODUCT BULLETIN & COLOR CARD * FDA/EU compliance information available upon request; exceptions may occur Color Pantone Reference PE Base PP Base Transparent PP Base PEBA Base PC Base Transparent PC Base* ABS Base* White — PE0M176031 PP0M176045 ** AH0M415001 NC0M176058 ** SB0M665206 Yellow 102C PE1M176076 PP1M176060 PP1M176062 AH1M415002 NC1M176058 NC1M176059 SB1M664958 Orange 158C PE2M176044 PP2M176046 ** ** NC2M176044 NC2M664912 SB2M664939 Red 199C PE3M176131 PP3M176111 PP3M176113 AH3M415002 NC3M176116 NC3M176122 SB3M665037 Pink 196C PE3M176130 PP3M176109 ** AH3M415001 NC3M176117 NC3M665052 SB3M665039 Violet 2593C PE4M176023 PP4M176036 PP4M176039 AH4M415001 NC4M176038 NC4M176044 SB4M664978 Light Blue 292C PE5M176155 PP5M176169 ** AH5M415003 NC5M176142 ** SB5M665402 Mid Blue 285C PE5M176154 PP5M176171 PP5M176175 AH5M415002 NC5M176143 NC5M176146 SB5M665404 Dark Blue 288C PE5M176153 PP5M176173 ** ** NC5M176144 ** SB5M665406 Light Green 346C PE6M176128 PP6M176111 ** ** NC6M176118 ** SB6M665070 Bluish Green 3145C PE6M176126 PP6M176115 ** ** NC6M176119 ** SB6M665068 Medium Green 348C PE6M176127 PP6M176113 PP6M176118 AH6M415001 NC6M176120 NC6M176121 SB6M665072 Dark Gray 425C PE7M176066 PP7M176091 PP7M176094 ** NC7M176124 ** SB7M665297 Mid Gray Cool Gray 5C PE7M176067 PP7M176089 ** AH7M415001 NC7M176125 NC7M665175 SB7M665295 Beige 7502C PE8M176048 PP8M176058 ** ** NC8M176058 ** SB8M664871 Brown 463C/731C PE8M176049 PP8M176060 ** ** NC8M176059 ** SB8M664869 Black Black C PL9M176008 PP9M176017 ** ** NC9M176008 NC9M176009 SB9M664896 Colors may vary from actual color shown. It is the responsibility of the medical device manufacturer and the person placing the medical device on the market to ensure compliance of the medical device with all applicable laws and regulations, including the suitability of all raw materials and components used for its manufacture.

FDA/EU compliance information available upon request REMAFIN™ EP White Colorants for Pharmaceutical Packaging REMAFIN™ EP is a range of PE and PP based masterbatches designed for protecting oral, topical, parenteral, ophthalmic and nasal pharmaceuticals by opacifying primary and secondarypharmaceutical packaging. KEY CHARACTERISTICS • Manufactured under change control principles beyond CAS number (similar level as MEVOPUR concentrates), reducing risk of change • Free from animal-derived substances and phthalates • Suitable for blown film, injection molding, blow molding and extrusion REGULATORY SUPPORT • Raw materials tested to: - ISO 10993-1 - USP chapters , including Class VI, a requirement for ophthalmic and nasal drugs - European Pharmacopeia 3.1.3/3.1.5 (polyolefin) - USP (polyethylene) - ICH Q3D elemental impurities - USP and USP light transmission • Registered Drug Master File (Type III) • Food contact compliance established with FDA/EU* APPLICATION BULLETIN CARRIER MATERIAL PIGMENT CONTENT/TYPE LIGHT FASTNESS THERMAL STABILITY PRODUCT CODE HDPE 50% TiO2 8 300°C PH00075525 LLDPE 60% TiO2 8 300°C PL00075542 LLDPE 70% TiO2 8 300°C PL00075545 PP 50% TiO2 8 300°C PP00075717 Healthcare use limitations apply—see below. It is the responsibility of the medical device manufacturer and the person placing the medical device on the market to ensure compliance of the medical device, including the suitability of all raw materials and components used for its manufacture, and with all applicable laws and regulations. 1.844.4AVIENT www.avient.com

& Canada EMEA Asia Latin America 64% 36% Specialty Engineered Materials Color Additives and Inks 40% 37% 18% 5% 6% 8% 24% 20% 10% 15% 9% 4% 4% Defense Healthcare Packaging Consumer Building & Construction Industrial Transportation Energy Telecom Geography Segment Industry 4 CRE AT ING A WORL D-CL AS S S US TAINABL E ORGANIZ AT ION 1. 6% annualized long term sales growth leveraging sustainable solutions, composites, healthcare and emerging regions 2. Avient 2011, 2018 and 2021 multiples reflect trailing 12 months EBITDA at December 31. 28 EV / 2023E EBITDA 6.5 8.5 11.0 8.9 12.0 11.9 10.9 9.9 8.2 16.3 13.8 11.9 9.6 9.5 9.5 9.2 7.7 20 11 20 18 20 21 O ct 20 23 A V Y R P M P P G K W R FU L E C L H X L S C L A S H FM C C E H U N E M N Avient Historic Multiple Avient Specialty Formulators Other Specialty / Chemical Companies A P P E N D I X 30 Performance Additives 16% Pigments 12% TiO2 10% Dyestuffs 2% Polyethylene 11% Nylon 6% Polypropylene 5% Styrenic Block Copolymer 5% Other Raw Materials 33% ~40% hydrocarbon based (Grey shaded materials are hydrocarbon based, includes portion of “Other Raw Materials”) Non-hydrocarbon based materials 2022 pro forma results for the acquisition of Avient Protective Materials RA W MATERIAL BASKET SEGMENT DATA U.S. & Canada 40% EMEA 37% Asia 18% Latin America 5% 2022 PRO FORMA SEGMENT, END MARKET AND GEOGRAPHY GEOGRAPHY REVENUESEGMENT FINANCIALS Consumer 20% Packaging 24% Industrial 15% Building and Construction 10% Telecommunications 4% Energy 4% Defense 6% END MARKET REVENUE $2,355M $402M $1,300M $272M Sales EBITDA Specialty Engineered Materials Color Additives and Inks $592M$3,653M (1) Transportation 9% Healthcare 8% 32 (1) Total company sales and adjusted EBITDA of $3,653M and $592M, respectively, include intercompany sales eliminations and corporate costs 2 0 2 2 R E V E N U E | $ 2 . 4 B I L L I O N US & Canada 34% EMEA 38% Asia 20% Latin America 8% END MARKET REGION 33 Packaging 34% Consumer 21% Healthcare 8% Industrial 15% Transportation 8% Building & Construction 11% Telecommunications 1% Energy 2% COLOR, ADDITIVES & INKS 2 0 2 2 P R O F O R M A R E V E N U E | $ 1 . 3 B I L L I O N US & Canada 52% EMEA 35% Asia 13% 34 Packaging 5% Consumer 19% Healthcare 8%Industrial 16% Transportation 10% Telecommunications 10% Energy 9% Defense 15% Building & Construction 8% END MARKET REGION SPECIALTY ENGINEERED MATERIALS Packaging 32% Consumer 27% Healthcare 8% Industrial 14% Building & Construction 5% Telecommunications 3% Energy 1% Defense 1% Asia (18% of sales) Transportation 9% 2 0 2 2 P R O F O R M A AV I E N T R E G I O N A L S A L E S Packaging 27% Consumer 14% Healthcare 5% Industrial 17% Building & Construction 10% Energy 5% Defense 8% EMEA (37% of sales)Transportation 11% Packaging 13% Consumer 24% Healthcare 12% Industrial 15% Building & Construction 13% Energy 5% Defense 5% US & Canada (40% of sales) Transportation 7% Packaging 56% Consumer 23% Healthcare 4% Industrial 7% Building & Construction 4% Telecommunications 1% LATAM (5% of sales) Transportation 5% Telecommunications 3% Telecommunications 6% 35 B Y E N D M A R K E T Reconciliation of Non-GAAP Financial Measures (Unaudited) (Dollars in millions, except for per share data) Senior management uses comparisons of adjusted net income from continuing operations attributable to Avient shareholders and diluted adjusted earnings per share (EPS) from continuing operations attributable to Avient shareholders, excluding special items, to assess performance and facilitate comparability of results. Three Months Ended September 30, 2023 Three Months Ended September 30, 2022 Reconciliation to Condensed Consolidated Statements of Income: $ EPS $ EPS Net income (loss) from continuing operations attributable to Avient shareholders $ 5.1 $ 0.06 $ (27.4) $ (0.30) Special items, after tax 32.0 0.35 68.3 0.75 Amortization expense, after-tax 15.2 0.16 $ 13.4 $ 0.14 Adjusted net income / EPS $ 52.3 $ 0.57 $ 54.3 $ 0.59 Three Months Ended September 30, Reconciliation to EBITDA and Adjusted EBITDA: 2023 2022 Sales - GAAP $ 753.7 $ 823.3 Pro Forma APM adjustments — 60.7 Pro forma adjusted sales $ 753.7 $ 884.0 Net income from continuing operations – GAAP $ 5.1 $ (27.8) Income tax (benefit) expense (0.1) (1.2) Interest expense, net 30.3 37.3 Depreciation and amortization 46.4 39.8 EBITDA from continuing operations $ 81.7 $ 48.1 Special items, before tax 43.2 82.0 Interest expense included in special items (2.2) (10.0) Depreciation and amortization included in special items — (0.8) Adjusted EBITDA $ 122.7 $ 119.3 Pro forma APM adjustments — 17.2 Pro forma adjusted EBITDA $ 122.7 $ 136.5 Pro forma adjusted EBITDA as a % of sales 16.3 % 15.4 % 1 Year Ended December 31, Reconciliation to EBITDA and Adjusted EBITDA: 2006 2018 Sales $ 2,622.4 $ 3,533.4 Net income from continuing operations – GAAP $ 133.5 $ 160.8 Income tax expense 29.7 36.4 Interest expense, net 63.1 62.8 Depreciation and amortization 57.1 91.5 EBITDA from continuing operations $ 283.4 $ 351.5 Special items, before tax (34.0) 59.5 Depreciation and amortization included in special items — (3.0) JV - equity income (107.0) — Adjusted EBITDA $ 142.4 $ 408.0 Adjusted EBITDA as a % of sales 5.4 % 11.5 % Reconciliation to EBITDA and Adjusted EBITDA: Three Months Ended December 31, 2022 Net loss from continuing operations – GAAP $ (16.6) Income tax benefit (60.8) Interest expense, net 49.4 Depreciation and amortization 48.6 EBITDA from continuing operations $ 20.6 Special items, before tax 104.3 Interest expense included in special items (16.0) Depreciation and amortization included in special items (1.5) Adjusted EBITDA $ 107.4 Reconciliation of Pro Forma Adjusted Earnings per Share: Three Months Ended December 31, 2022 Net loss from continuing operations attributable to Avient shareholders $ (17.0) Special items, after tax 38.3 Amortization expense, after-tax 14.6 Adjusted net income from continuing operations excluding special items 35.9 Pro forma adjustments* 2.5 Pro forma adjusted net income from continuing operations attributable to Avient shareholders $ 38.4 Weighted average diluted shares 91.7 Pro forma adjusted EPS - excluding special items pro forma for APM acquisition $ 0.42 * Pro forma adjustment to reflect APM results for the period before Avient ownership including the impacts of debt financing and paydown of debt with net proceeds from the Distribution sale. 2 AVNT November IR Presentation (11.3) 3PM Avient corporation�investor presentation DISCLAIMER Slide Number 3 Creating a world-class�sustainable organization Top-tier sustainability performance�and recognition What we do: We are a formulator Slide Number 7 Avient protective materials �First Year Slide Number 9 Slide Number 10 Slide Number 11 Slide Number 12 Slide Number 13 Slide Number 14 Slide Number 15 Slide Number 16 Slide Number 17 Slide Number 18 Slide Number 19 Slide Number 20 Slide Number 21 Slide Number 22 Slide Number 23 Slide Number 24 Slide Number 25 Avient is asset light Free cash flow conversion Multiple expansion Slide Number 29 Slide Number 30 Slide Number 31 2022 pro forma segment, end market and Geography Color, Additives & Inks Specialty Engineered Materials Slide Number 35 IR Deck - AVNT-2023.09.30 Non GAAP Recs Attachment

INK BLUE 19-4234TPX

A reconciliation of these measures to their most directly comparable GAAP measures is provided in the tables below. 1 Reconciliation of EBITDA by Segment Three Months Ended December 31, Year Ended December 31, 2020 2019 2020 2019 Sales: Color, Additives and Inks $ 525.8 $ 226.7 $ 1,502.9 $ 1,003.8 Specialty Engineered Materials 190.6 177.5 708.8 745.7 Distribution 305.1 272.4 1,110.3 1,192.2 Corporate and eliminations (24.5) (18.0) (79.9) (79.0) Sales $ 997.0 $ 658.6 $ 3,242.1 $ 2,862.7 Operating income: Color, Additives and Inks $ 57.5 $ 27.2 $ 180.8 $ 147.4 Specialty Engineered Materials 30.4 18.8 94.4 83.7 Distribution 18.0 17.0 69.5 75.4 Corporate and eliminations (40.9) (42.5) (155.4) (149.7) Operating Income $ 65.0 $ 20.5 $ 189.3 $ 156.8 Items Below Operating Income in Corporate: Other income, net $ 11.7 $ 10.7 $ 24.3 $ 12.1 Depreciation & amortization: Color, Additives and Inks $ 27.3 $ 10.7 $ 75.1 $ 42.7 Specialty Engineered Materials 7.4 7.0 30.0 29.5 Distribution 0.3 0.1 0.7 0.5 Corporate and eliminations 2.8 1.0 9.3 5.4 Depreciation & Amortization $ 37.8 $ 18.8 $ 115.1 $ 78.1 EBITDA: Color, Additives and Inks $ 84.8 $ 37.9 $ 255.9 $ 190.1 Specialty Engineered Materials 37.8 25.8 124.4 113.2 Distribution 18.3 17.1 70.2 75.9 Corporate and eliminations (26.4) (30.8) (121.8) (132.2) EBITDA $ 114.5 $ 50.0 $ 328.7 $ 247.0 EBITDA as a % of sales: Color, Additives and Inks 16.1 % 16.7 % 17.0 % 18.9 % Specialty Engineered Materials 19.8 % 14.5 % 17.6 % 15.2 % Distribution 6.0 % 6.3 % 6.3 % 6.4 % Corporate and eliminations nm nm nm nm Total Company 11.5 % 7.6 % 10.1 % 8.6 % nm - not meaningful 2 Three Months Ended December 31, Year Ended December 31, Reconciliation to Adjusted EBITDA: 2020 2019 2020 2019 Net income from continuing operations – GAAP $ 74.7 $ 6.4 $ 133.8 $ 75.7 Income tax expense (17.3) 12.9 5.2 33.7 Interest expense 19.3 11.9 74.6 59.5 Depreciation and amortization from continuing operations 37.8 18.8 115.1 78.1 EBITDA $ 114.5 $ 50.0 $ 328.7 $ 247.0 Special items, before tax 4.2 15.0 66.2 61.7 Interest expense included in special items — — (10.1) — Accelerated depreciation included in special items (0.7) — (3.2) — Adjusted EBITDA $ 118.0 $ 65.0 $ 381.6 $ 308.7 Three Months Ended December 31, 2020 Reconciliation of Adjusted Earnings per Share: Avient Special Items Adjusted Avient Sales $ 997.0 $ — $ 997.0 Operating income $ 65.0 $ 14.6 $ 79.6 Interest expense, net (19.3) — (19.3) Other income, net 11.7 (10.4) 1.3 Income taxes 17.3 (30.9) (13.6) Net income from continuing operations attributable to Avient shareholders $ 74.2 $ (26.7) $ 47.5 Weighted average diluted shares 92.1 Adjusted EPS - excluding special items $ 0.52 Reconciliation of Adjusted EBITDA from continuing operations: Operating income and other income, net $ 76.7 $ 4.2 $ 80.9 Depreciation and amortization 37.8 (0.7) 37.1 EBITDA from continuing operations $ 114.5 $ 3.5 $ 118.0 EBITDA as a % of sales 11.8 % 3 Three Months Ended December 31, 2019 Reconciliation of Pro Forma Adjusted Earnings per Share: Avient Special Items Adjusted Avient Clariant MB Pro Forma Adjustments(1) Pro Forma Adjusted Avient Sales $ 658.6 $ — $ 658.6 $ 263.5 $ 922.1 Operating income $ 20.5 $ 24.6 $ 45.1 $ 13.2 $ 58.3 Interest expense, net (11.9) — (11.9) (11.1) (23.0) Other income, net 10.7 (9.6) 1.1 — 1.1 Income taxes (12.9) 4.9 (8.0) (0.5) (8.5) Net income from continuing operations attributable to Avient shareholders $ 6.4 $ 19.9 $ 26.3 $ 1.6 $ 27.9 Weighted average diluted shares 77.5 Impact to diluted shares from January 2020 equity offering 15.3 Pro forma weighted average diluted shares 92.8 Pro forma adjusted EPS $ 0.30 Reconciliation of Pro Forma Adjusted EBITDA from continuing operations: Operating income and other income, net $ 31.2 $ 15.0 $ 46.2 $ 13.2 $ 59.4 Depreciation and amortization 18.8 — 18.8 15.1 33.9 EBITDA from continuing operations $ 50.0 $ 15.0 $ 65.0 $ 28.3 $ 93.3 EBITDA as a % of sales 10.1 % (1) - Pro forma adjustments for the periods prior to the acquisition date (July 1, 2020) and to give effects of the financing for the acquisition Year Ended December 31, 2020 Reconciliation of Pro Forma Adjusted Earnings per Share: Avient Special Items Adjusted Avient Clariant MB Pro Forma Adjustments(1) Pro Forma Adjusted Avient Sales $ 3,242.1 $ — $ 3,242.1 $ 540.4 $ 3,782.5 Operating income $ 189.3 $ 73.7 $ 263.0 $ 45.0 $ 308.0 Interest expense, net (74.6) 10.1 (64.5) (18.1) (82.6) Other income, net 24.3 (17.6) 6.7 — 6.7 Income taxes (5.2) (41.4) (46.6) (6.2) (52.8) Net income attributable to noncontrolling interests (1.8) — (1.8) — (1.8) Net income from continuing operations attributable to Avient shareholders $ 132.0 $ 24.8 $ 156.8 $ 20.7 $ 177.5 Weighted average diluted shares 90.6 Impact to diluted shares from January 2020 equity offering 1.5 Pro forma weighted average diluted shares 92.1 Pro forma adjusted EPS $ 1.93 Reconciliation of Pro Forma Adjusted EBITDA from continuing operations: Operating income and other income, net $ 213.6 $ — $ 56.1 $ 269.7 $ 45.0 $ — $ 314.7 Depreciation and amortization 115.1 (3.2) 111.9 30.1 142.0 EBITDA from continuing operations $ 328.7 $ 52.9 $ 381.6 $ 75.1 $ 456.7 EBITDA as a % of sales 12.1 % (1) - Pro forma adjustments for the periods prior to the acquisition date (July 1, 2020) and to give effects of the financing for the acquisition 4 Year Ended December 31, 2019 Reconciliation of Pro Forma Adjusted Earnings per Share: Avient Special Items Adjusted Avient Clariant MB Pro Forma Adjustments(1) Pro Forma Adjusted Avient Sales $ 2,862.7 $ — $ 2,862.7 $ 1,118.6 $ 3,981.3 Operating income $ 156.8 $ 71.7 $ 228.5 $ 72.9 $ 301.4 Interest expense, net (59.5) — (59.5) (33.4) (92.9) Other income, net 12.1 (10.0) 2.1 — 2.1 Income taxes (33.7) (5.9) (39.6) (9.1) (48.7) Net income attributable to noncontrolling interests (0.2) — (0.2) — (0.2) Net income from continuing operations attributable to Avient shareholders $ 75.5 $ 55.8 $ 131.3 $ 30.4 $ 161.7 Weighted average diluted shares 77.7 Impact to diluted shares from January 2020 equity offering 15.3 Pro forma weighted average diluted shares 93.0 Pro forma adjusted EPS $ 1.74 Reconciliation of Pro Forma Adjusted EBITDA from continuing operations: Operating income and other income, net $ 168.9 $ — $ 61.7 $ 230.6 $ 72.9 $ — $ 303.5 Depreciation and amortization 78.1 — 78.1 60.3 138.4 EBITDA from continuing operations $ 247.0 $ 61.7 $ 308.7 $ 133.2 $ 441.9 EBITDA as a % of sales 11.1 % (1) - Pro forma adjustments for the periods prior to the acquisition date (July 1, 2020) and to give effects of the financing for the acquisition Three Months Ended March 31, 2020 Reconciliation of Pro Forma Adjusted Earnings per Share: Avient Special Items Adjusted Avient Clariant MB Pro Forma Adjustments(1) Pro Forma Adjusted Avient Sales $ 711.5 $ — $ 711.5 $ 279.4 $ 990.9 Operating income 52.8 9.7 62.5 23.0 85.5 Interest expense, net (9.4) — (9.4) (12.8) (22.2) Other income, net 1.6 (0.1) 1.5 — 1.5 Income taxes (11.9) (1.0) (12.9) (2.4) (15.3) Net income from continuing operations attributable to Avient shareholders $ 33.1 $ 8.6 $ 41.7 $ 7.8 $ 49.5 Weighted average diluted shares 86.7 Impact to diluted shares from January 2020 equity offering 6.1 Pro forma weighted average diluted shares 92.8 Pro forma adjusted EPS $ 0.53 (1) - Pro forma adjustments for the periods prior to the acquisition date (July 1, 2020) and to give effects of the financing for the acquisition 5 Three Months Ended December 31, 2019 Year Ended December 31, 2019 Reconciliation of pro forma sales, operating income, and EBITDA: CAI Clariant MB Pro Forma Adjustments(1) Pro Forma CAI CAI Clariant MB Pro Forma Adjustments(1) Pro Forma CAI Sales $ 226.7 $ 263.5 $ 490.2 $ 1,003.8 $ 1,118.6 $ 2,122.4 Operating income $ 27.2 $ 13.2 $ 40.4 $ 147.4 $ 72.9 $ 220.3 EBITDA $ 37.9 $ 28.3 $ 66.2 $ 190.1 $ 133.2 $ 323.3 EBITDA as a % of sales 13.5 % 15.2 % (1) - Pro forma adjustments for the periods prior to the acquisition date (July 1, 2020) and to give effects of the financing for the acquisition Year Ended December 31, 2020 Reconciliation of pro forma sales, operating income, and EBITDA: CAI Clariant MB Pro Forma Adjustments(1) Pro Forma CAI Sales $ 1,502.9 $ 540.4 $ 2,043.3 Operating income $ 180.8 $ 45.0 $ 225.8 EBITDA $ 255.9 $ 75.1 $ 331.0 EBITDA as a % of sales 16.2 % (1) - Pro forma adjustments for the periods prior to the acquisition date (July 1, 2020) and to give effects of the financing for the acquisition Free cash flow, defined as cash provided by operating activities excluding items associated with acquisitions and divestitures, less capital expenditures, is considered a non-GAAP financial measure.

V I S I O N PolyOne Corporation 4 To be the world’s premier provider of specialized polymer materials, services and solutions C O R E V A L U E S P E R S O N A L V A L U E S Honesty IntegrityRespect Operational Excellence Commercial Excellence Specialization Globalization Collaboration ExcellenceInnovation To be the world’s premier provider of specialized polymer materials, services and solutions S A F E T Y F I R S T PolyOne Corporation 5 Injuries per 100 Workers Spartech Acquisition 1.3 1.1 1.1 0.85 0.65 0.57 0.54 0.97 0.84 0.74 0.74 0.69 0.51 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 PolyOne Corporation 6 P O L Y O N E P O S T P P & S D I V E S T M E N T 2 0 1 8 R E V E N U E | $ 2 . 9 B I L L I O N Segment End Market Geography Transportation 17% Healthcare 16% Industrial 15% Packaging 13% Consumer 13% Wire & Cable 8% Building & Construction 7% Electrical & Electronics 6% Appliance 4% Color Additives & Inks 35% Distribution 43% Specialty Engineered Materials 22% United States 53% Europe 19% Asia 12% Canada 5% Latin America 11% 2009 2010 2011 2012 2013 2014 2015 2016* 2017* 2018 $2.43 P R O O F O F P E R F O R M A N C E C O N S E C U T I V E Y E A R S PolyOne Corporation 7 9 $0.13 $0.68 $0.82 $1.00 $1.31 $1.80 $1.96 $2.06 $2.21 *Pro Forma for sale of DSS 2006 2018 ROIC** 5.0% 14.1% Operating Income % of Sales Color, Additives & Inks 1.7% 15.1% Specialty Engineered Materials 1.1% 11.2% Performance Products & Solutions 4.3% 10.0% Distribution 2.6% 5.6% **ROIC is defined as TTM adjusted OI after tax divided by the sum of average debt and equity less cash over a 5 quarter period A D J U S T E D E P S E X P A N S I O N S U S T A I N A B L E P A T H T O D O U B L E - D I G I T E P S G R O W T H PolyOne Corporation 8 P E O P L E P R O D U C T S P L A N E T P E R F O R M A N C E Double digit annual EPS growth Expand specialty portfolio with strategic acquisitions Innovate and develop new technologies and services Repurchase 600K-1M shares annually Increase commercial resources 5-7% annually Double acquired company margins Enhance efficiencies through Lean Six Sigma and commercial excellence 531 710130 164 504 663 2014 2018 R&D / Technical Marketing Sales PolyOne Corporation 9 Increased commercial headcount + 34% + 26% + 32% I N V E S T M E N T I N C O M M E R C I A L R E S O U R C E S D R I V I N G G R O W T H Sustained revenue increases led by organic business $2.9 $2.9 $3.2 $3.5 2015 2016 2017 2018 Total + 9% Organic + 5% Revenue in billions of $ Total + 10% Organic + 7% Lead Specialists T H E E V O L V I N G C U S T O M E R R E L A T I O N S H I P PolyOne Corporation 10 Expanded Path Traditional Path Strategic Accounts/ Field Sales Business Development Customer Service Web and Social Media Inside Sales PolyOne Corporation 11 Investments in digital and dedicated inside sales to improve customer experience 110% increase in leads (from 6,000 to 12,700) driven by website, phone, and online chat E X P A N D E D P A T H A D D I N G C U S T O M E R T O U C H P O I N T S 4 24 2014 2018 Inside sellers $11M $109M 2014 2018 Inside sales/digital revenue A L I G N I N G W I T H T R E N D S F O R G R O W T H T R A N S P O R T A T I O N P A C K A G I N G H E A L T H C A R E C O N S U M E R PolyOne Corporation 12 Facilitate alternative energy solutions Light- weighting Reduce packaging materials Improve recyclability Reduce spread of infection I N N O V A T I O N PolyOne Corporation 13 Customization 55% M&A 30% Innovation Pipeline 15% Innovation comes from Research & Development Spend ($ millions) Vitality Index % of sales from products launched last 5 years 12% 35% 2006 2018 $20 $56 2006 2018 Transformational Opportunity for Growth Through M&A Adjacent Opportunity for Growth Through New Product Pipeline Core Customization 3 H O R I Z O N S O F D E V E L O P M E N T PolyOne Corporation 14 Incremental development from existing base of technology New development adjacent to current technology New technology development outside of and with our current base Service adjacent markets and customers Create new markets, target new customer needs Service existing markets and customers Market Technical I N N O V A T I O N Non-Halogen Flame Retardants Barrier Technologies Fiber Colorants Advanced Composites Thermoplastic Elastomers Gordon Composites/ Polystrand – Composites GLS – Thermoplastic Elastomers ColorMatrix – Liquid Color & Additives PlastiComp Fiber-Line I N N O V A T I O N P I P E L I N E PolyOne Corporation 15 PrototypeFrame Opportunity Scale-up & Test Market Build Business Case Commercial Launch (since 2017) Phase 1 Phase 2 Phase 3 Phase 4 Phase 5 5 8 2 3 3 3 44 0 1 4 5 1 1 3 Breakthrough Platform Derivative Number of Projects 10 5 17 5 10 47 Total Addressable Market ($ millions) - - $1,767 $315 $766 $2,848 F L A M E R E T A R D A N T P O L Y M E R S A D V A N C E D C O M P O S I T E S B A R R I E R M A T E R I A L S C O L O R A N T T E C H N O L O G I E S T H E R M O P L A S T I C E L A S T O M E R S I N N O V A T I O N S P O T L I G H T : C O M P O S I T E S PolyOne Corporation 16 C O M P O S I T E S R E F R E S H E R PolyOne Corporation 17 Fiber Polymer Composite Strength Design Flexibility Continuous Fiber Thermoset Composites Short Glass Fiber Thermoplastics Continuous Fiber Thermoplastic Composites Long Glass Fiber Thermoplastics S T R A T E G I C I N V E S T M E N T H I S T O R Y Acquired Polystrand Installed LFT production Avon Lake Acquired Gordon Composites Thermoplastic Composites Long Fiber Reinforced Thermoplastics Continuous Fiber Thermosets Long Fiber Thermoplastic (LFT) Technology Installed LFT production Barbastro, Spain Acquired Glasforms Long Fiber Reinforced Thermoplastics Continuous Fiber Thermosets 2012 2015 20162009 2011 Acquired PlastiComp, specialty LFT producer 2018 PolyOne Corporation 2019 Acquired Fiber-Line, specialty fiber processor 18 C O M P O S I T E S I N T R A N S P O R T A T I O N PolyOne Corporation 19 W A T E R C R A F TR A I L H E A V Y T R U C K Bulkheads and Transoms Ceilings and Hatches Doors and Cabinetry Flooring Door Panels Side Walls Flooring & Side Panels Aerodynamic Fairings Seat and Bunk Reinforcements F I B E R - L I N E H I G H L I G H T S PolyOne Corporation 20 71% 16% 12% 1% 2018PF Sales by Market Fiber Optics Industrial Oil & Gas Consumer Estimated 2019 Sales: $100M • Abrasion resistance • Adhesion enhancement • Anti-microbial • Chemical resistance • Color • Conductivity • Fire retardant • Glow-in-the- dark • Process enhancement • UV inhibitor • Water swellable • Water repellency • Entangling • Extrusion • Pultrusion • Twisting • Winding • Braiding • Stranding High Performance Fiber and Polymers Suppliers Customer Value Coating Technology Processing Technology Fiber-Line Bare and Coated Fiber and Composite Rod Customers Fiber Processing Capabilities Polymer Formulation Capabilities P O L Y O N E A P P L I C A T I O N S I N F I B E R O P T I C C A B L E S PolyOne Corporation 21 1. T H E N E W P O L Y O N E : A S P E C I A L T Y G R O W T H C O M P A N Y  Growing leadership position in attractive markets  Innovation, technology and service are differentiators  Capital management is a strength: Record-setting cash generation to continue for years  Expand ROIC while increasing invested capital  Proven acquisition strategy with robust pipeline  Commercial investments are fueling momentum and generating organic growth S E R V I C E : T H E T I M E L E S S D I F F E R E N T I A T O R PolyOne Corporation 31 T A L E N T D E V E L O P M E N T PolyOne Corporation 32 Leadership Program Participants 2012 2013 2014 2015 47 0 86 2016 2018 125 169 315 Campus Hires 2008 2011 2014 2017 0 25 90 47 PolyOne LSS Blackbelts 2008 2011 2014 2018 0 67 220 147 2018 141 A U N I Q U E C U S T O M E R E X P E R I E N C E Industrial Design I Q D E S I G N L A B S PolyOne Corporation 33 Material & Color Expertise Manufacturing Expertise 3 14 2014 2018 Industrial designers $0 $10M 2014 2018 $4M $80M 2014 2018 Opportunity funnel New business revenue L S S C U S T O M E R F I R S T PolyOne Corporation 34 Customer Projects Enables sales growth by building more intimate customer relationships, giving us insight to customers’ needs, with a service that is not easily replicated 2014 2018 2 104 3 D P R I N T I N G B R I N G I N G N E W I D E A S T O L I F E PolyOne Corporation 35 Enables validation of fit and function Shortens design cycle and time to market Avoids tooling rework Drives innovation Delivers substantial customer value PolyOne Corporation 36 From concept to production M O N T H M O N T H M O N T H M O N T H M O N T H M O N T H 99.9% Reduction in turnaround time Traditional Timeline up to 24 weeks PolyOne ColorMatrix Select™ 6 hours Innovative system for processors and OEMs to develop colors in real time Complete system that provides customers with the freedom to match, prototype and produce color entirely within their own facility C O L O R M A T R I X S E L E C T ™ “Being able to create color and produce parts in 1 day is unheard of in this industry” -CEO, Industry Leader I N N O V A T I N G W I T H P O L Y O N E PolyOne Corporation 37 S E G M E N T H I G H L I G H T S C O L O R , A D D I T I V E S & I N K S E N D M A R K E T S & S O L U T I O N S PolyOne Corporation 38 Solid Colorants Performance Additives Screen Printing Inks Liquid Colorants Packaging 28% Industrial 14% Textiles 13% Wire & Cable 11% Building & Construction 10% Transportation 8% Consumer 8% Healthcare 5% Appliances 2% Electrical & Electronic 1% Operating Income & MarginRevenue by Region C O L O R , A D D I T I V E S & I N K S 2 0 1 8 R E V E N U E | O V E R $ 1 B I L L I O N $4 $25 $104 $159 0.9% 5.5% 12.2% 15.1% 0.0% 2.0% 4.0% 6.0% 8.0% 10.0% 12.0% 14.0% 16.0% 20 30 40 50 60 70 80 90 100 110 120 130 140 150 160 170 2005 2009 2013 2018 PolyOne Corporation 39 Europe 35% United States 45% Asia 14% Canada 1% Mexico 3% South America 2% S P E C I A L T Y E N G I N E E R E D M A T E R I A L S E N D M A R K E T S & S O L U T I O N S PolyOne Corporation 40 Engineered Formulations Advanced Composites Thermoplastic Elastomers Consumer 21% Transportation 18% Wire & Cable 13%Healthcare 9% Industrial 9% Packaging 7% Appliance 3% Building & Construction 4% Electrical & Electronics 16% S P E C I A L T Y E N G I N E E R E D M A T E R I A L S Revenue by Region Operating Income & Margin 2 0 1 8 R E V E N U E | $ 6 4 6 M I L L I O N PolyOne Corporation 41 $21 $57 $72 0.1% 5.1% 9.3% 11.2% 0.0% 2.0% 4.0% 6.0% 8.0% 10.0% 12.0% 20 30 40 50 60 70 80 90 2005 2009 2013 2018 Europe 28% United States 46% Asia 24% Canada 2% P E R F O R M A N C E P R O D U C T S & S O L U T I O N S E N D M A R K E T S & S O L U T I O N S PolyOne Corporation 42 Specialty Vinyl Solutions Healthcare Formulations Smart Device Materials Flame Retardant Polymers Building & Construction 28% Industrial 18% Transportation 17% Wire & Cable 16%Consumer 7% Appliance 6% Packaging 4% Electrical & Electronics 4% Asia 2% United States 78% Mexico 5% Canada 15% P E R F O R M A N C E P R O D U C T S & S O L U T I O N S Operating Income & MarginRevenue by Region 2 0 1 8 R E V E N U E | $ 7 3 6 M I L L I O N $40 $24 $56 $74 4.6% 3.6% 7.2% 10.0% 0.0% 2.0% 4.0% 6.0% 8.0% 10.0% 12.0% 14.0% 16.0% 0 10 20 30 40 50 60 70 80 90 100 2005 2009 2013 2018 PolyOne Corporation 43 D I S T R I B U T I O N E N D M A R K E T S & S U P P L I E R S PolyOne Corporation 44 Healthcare 27% Transportation 22% Industrial 18% Consumer 12% Appliance 6% Electrical & Electronics 5% Building & Construction 5% Packaging 3% Wire & Cable 2% $20 $25 $63 $71 2.9% 4.0% 5.9% 5.6% 0.0% 1.0% 2.0% 3.0% 4.0% 5.0% 6.0% 7.0% 15 25 35 45 55 65 75 2005 2009 2013 2018 Operating Income & Margin2018 Revenue | $1.3 Billion http://www.avient.com/Pages/VariationRoot.aspx O V E R V I E W O F R A W M A T E R I A L P U R C H A S E S PolyOne Corporation 45 Performance Additives 15% PVC 11% Pigments 9% Polyethylene 8% Plasticizers 7% Polypropylene 7% TiO2 6% Nylon 5% Styrenic Block Copolymer 5% Other Raw Materials 27% $1.3 billion of raw material purchases in 2018 excluding Distribution business Note: All figures exclude Distribution business T A R G E T E N D M A R K E T S & A P P L I C A T I O N E X A M P L E S PolyOne Corporation 46 Thermally Conductive Technologies Chemical Resistant Technologies Polymer Colorants Elastomeric Grips and Handles Structural Composites Antimicrobial Technologies Anti-Counterfeiting Technologies Target End Markets… Healthcare Catheter Technologies Under-hood Components Target End Markets… Automotive Interior Structural Components Sound & Vibration Management Roof Systems Air Management Electronics and Cameras Lighting Exterior / Interior Trim Braces & Brackets Fasteners Seals & Flaps Target End Markets… Consumer Thermally Conductive Components Polymer Colorants Elastomeric Grips and Handles Structural Composite Components Oxygen Scavenger Technologies Laser Marking Additives Antistatic Technologies UV Light Barrier Technologies Cap & Closure Colorants Process Optimization Technologies Antioxidant Technologies Density Modified Technologies Target End Markets… Packaging  Impart weight, sound and metallic finish to caps and closures for cosmetics and spirits applications  Elevate quality and prestige perceptions among high-end consumers  Eliminate time and cost associated with secondary operations and assembly Luxury Packaging GravitechTM Density Modified Polymers  Eliminate costs by increasing pigment density  Enhance color performance without altering form and formulation  Increase design capabilities by reducing weight and layer thickness Optimize Color Usage OnColorTM Super Concentrates  Inhibit microbial growth on polymer surfaces  Enhance value or products and devices  Highly versatile concentrate with the ability to be incorporated into a wide variety of products Combat Bacteria Formation WithStandTM Antimicrobial Technology  Durable, long-lasting products stand up to the most aggressive disinfectants  Minimize environmental stress cracking and discoloration  One of the broadest medically approved polymer and colorant portfolios Medical Device Housings Chemically Resistant Engineered Polymers Color & Design Services  Greater control of color development and supply chain  Work across entire design process from concept to commercialization  Inspire creativity in the use of polymer materials, colors, and effects  Innovative brand differentiation  Faster development timelines Outdoor Applications  Leading provider of high performance specialty materials for the recreational and sports & leisure industry  Well positioned across all segments to address market needs  Metal to Polymer Conversion  Lightweighting  Thermal Management  Impact Performance  ColorMatrix Fiber Colorant Solutions  Proprietary advanced liquid color formulations and equipment enable greater efficiency and productivity  Eliminates aqueous dyeing and its associated wastewater treatment  Solid Color Concentrates  Extrusion-spun fibers colored via solid masterbatch Fiber Colorants Reconciliation of Non-GAAP Financial Measures (Unaudited) (Dollars in millions, except per share data) Senior management uses comparisons of adjusted net income from continuing operations attributable to PolyOne shareholders and diluted adjusted earnings per share (EPS) from continuing operations attributable to PolyOne shareholders, excluding special items, to assess performance and facilitate comparability of results. Service:�The Timeless differentiator Talent development IQ DESIGN LABS LSS CUSTOMER FIRST 3D Printing�Bringing New ideas to life Slide Number 36 Innovating with PolyOne COLOR, ADDITIVES & INKS Color, Additives & Inks Specialty Engineered Materials Specialty Engineered Materials Performance Products & Solutions Performance Products & Solutions DISTRIBUTION Overview of RAW MATERIAL PURCHASES Target end markets & �application examples Slide Number 47 Slide Number 48 Slide Number 49 Slide Number 50 Slide Number 51 Slide Number 52 Slide Number 53 Slide Number 54 Slide Number 55 Slide Number 56 Slide Number 57

All employees, supervisors, and members of management must accept individual responsibility for ensuring compliance with this policy. You are encouraged to contact your supervisor, your Human Resources representative, or the Corporate Human Resources department if you believe that there has been a violation of this policy, or you can notify the company’s EEO/AA compliance officer at PeopleLink@avient.com.

Compliance with laws and regulations is the duty of all Avient associates and of the Company itself. Complete required compliance and ethics training and certifications. All Avient associates are expected to report any non-compliance with this Code of Conduct immediately to any of the ethics and compliance resources described in the Code.

Compliance with specific regulatory requirements such as EU/US food contact, toy or UL 94 flammability classes is also available on request. BENEFITS • High additive loading for optimal UV stabilization • Solutions available for a large number of injection molded polymers including PP, PE, PS, HIPS, ABS, SAN, PA (nylon), PBT, Co-PET, PC, POM and TPU • Can be combined with colors and other additives in Smartbatch™ solutions • Formulations can be customized to meet specific regulatory compliance, e.g., EU and US food contact, toy, UL 94 recognition PRODUCT BULLETIN Copyright © 2023, Avient Corporation.